Metalone Plus 0.1%+0.025% (Ophthalmic Solution)

Indications

• Acute and chronic allergic non-infectious conjunctivitis treatment
• Keratitis treatment with severe swelling and intravascular injection
• Non-infectious inflammation of the anterior segment of the eye treatment
• Post-operative irritative conditions after strabismus surgery
• Post-operative irritative conditions after cataract surgery
• Post-operative irritative conditions after glaucoma surgery

Pharmacology

• Fluorometholone induction of phospholipase A2 inhibitory proteins
• Control of biosynthesis of potent mediators of inflammation
• Inhibition of release of arachidonic acid
• Tetrahydrozoline alpha agonist action
• Constriction of conjunctival blood vessels

Dosage & Administration

• Adult dosage: 1 drop into the conjunctival sac 2-3 times daily
• Increased adult dosage: 1 drop hourly for first one to two days for severe conditions
• Not established safety & effectiveness in children below 2 years of age

Interaction

• Interaction with antidepressant drugs inhibiting Mono Amino Oxidase (MAO) Enzyme

Contraindications

• Infectious conjunctivitis or keratitis
• Injuries or ulcerous processes of the cornea
• Glaucoma
• Diseases associated with stromal damage of the cornea or sclera
• Dry eyes

Side Effects

• Mild burning sensation
• Reversible increase in intraocular pressure
• Reactive hyperemia
• Cataract & corneal defects
• Glaucoma
• Systemic effects (chronic use)

Pregnancy & Lactation

• No adequate and well-controlled studies in pregnancy or while breastfeeding
• Use during pregnancy only if potential benefits justify potential risk to the fetus

Precautions & Warnings

• Avoid prolonged use
• Use after a careful risk-benefit evaluation in patients with severe blood circulation diseases
• Use after a careful risk-benefit evaluation in patients with metabolic disturbances
• Use after a careful risk-benefit evaluation in patients under treatment with MAOIs & other potentially hypertensive drugs
• Use after a careful risk-benefit evaluation in patients with a history of cataract
• Use after a careful risk-benefit evaluation in patients with herpes simplex infection
• Use after a careful risk-benefit evaluation in patients with rhinitis sicca

Overdose Effects

• Almost no likelihood of an overdose when used as directed
• CNS, cardiac and psychiatric disturbances in case of acute overdosage with tetryzoline
• Mydriasis
• Cyanosis and fever
• Administration of activated charcoal
• Gastric lavage
• Artificial ventilation with oxygen
• Use of phentolamine to lower blood pressure
• Vasopressors are contraindicated
• Antipyretic and anticonvulsive therapy in case of intoxication

Therapeutic Class

• Ophthalmic Steroid preparations

Storage Conditions

• Keep out of the reach of children
• Store in a cool, dry place away from heat and direct light
• Do not use more than 4 weeks after opening

Related Brands

• AFM-T 0.1%+0.025% (Ophthalmic Solution) - aristopharma-ltd
• Refemoline 0.1%+0.025% (Ophthalmic Solution) - reman-drug-laboratories-ltd
• Eylon 0.1%+0.025% (Ophthalmic Solution) - ibn-sina-pharmaceuticals-ltd